10-Q: Chain Bridge I Terminates Phytanix Bio Merger, Faces Delisting and Going Concern Doubts Amid Search for New Business Combination

Chain Bridge I, a blank check company, reported a net loss of $363,640 for Q1 2025, terminated its business combination agreement with Phytanix Bio, and continues to face significant liquidity challenges and delisting from Nasdaq, raising substantial doubt about its ability to continue as a going concern.

Summary

• Chain Bridge I reported a net loss of $363,640 for the three months ended March 31, 2025, a significant improvement from the $1,238,211 net loss in the same period of 2024.
• The company's cash balance decreased from $129,598 at December 31, 2024, to $17,565 at March 31, 2025.
• Total liabilities increased to $2,793,522 as of March 31, 2025, from $2,494,770 at December 31, 2024.
• The business combination agreement with Phytanix Bio was mutually terminated on April 7, 2025.
• The company's Class A ordinary shares and units were delisted from Nasdaq on November 19, 2024, and now trade on the OTCQB Market and Expert Market.
• The deadline to consummate an initial Business Combination has been extended to November 15, 2025.
• Fulton AC, the Sponsor, has made and committed to ongoing monthly contributions to the Trust Account to facilitate extensions, including $4,557 on November 16, 2024, and monthly thereafter, plus additional contributions totaling $18,236 between January and June 2025.
• Management identified a material weakness in internal control over financial reporting related to the adequate review and reconciliation of liabilities and prepaid expenses as of March 31, 2025.
• The company had a working capital deficit of $1,146,045 as of March 31, 2025.
• Income from investments held in the Trust Account significantly decreased to $55,415 in Q1 2025 from $343,520 in Q1 2024, partly due to a shift to U.S. treasury securities to mitigate Investment Company Act risks.

Sentiment

Score: 2

Explanation: The sentiment is highly negative due to the termination of the primary business combination, the delisting from Nasdaq, significant liquidity issues leading to a going concern warning, and an identified material weakness in internal controls. While the net loss decreased, the fundamental operational challenges and lack of a clear path forward outweigh this.

Positives

• Net loss significantly reduced to $363,640 in Q1 2025 from $1,238,211 in Q1 2024.
• General and administrative expenses decreased substantially to $191,850 in Q1 2025 from $510,056 in Q1 2024.
• Net cash used in operating activities decreased to $72,033 in Q1 2025 from $149,102 in Q1 2024.
• Sponsor (Fulton AC) continues to provide financial support through contributions to the Trust Account to extend the company's operational life.

Negatives

• The business combination agreement with Phytanix Bio was terminated on April 7, 2025, leaving the company without a target.
• The company's Class A ordinary shares and units were delisted from Nasdaq on November 19, 2024, and now trade on less liquid OTC markets.
• Cash balance significantly declined from $129,598 to $17,565 during the quarter.
• Total liabilities increased to $2,793,522 from $2,494,770.
• A working capital deficit of $1,146,045 as of March 31, 2025, raises substantial doubt about the company's ability to continue as a going concern.
• Management identified a material weakness in internal control over financial reporting.
• Income from investments held in the Trust Account decreased significantly due to a shift to lower-yielding U.S. treasury securities to avoid being deemed an unregistered investment company.

Risks

• Substantial doubt about the ability to continue as a going concern due to liquidity issues and mandatory liquidation date.
• Failure to consummate an initial Business Combination by November 15, 2025, which would lead to liquidation and warrants expiring worthless.
• Potential classification as an unregistered investment company under the Investment Company Act, which could force liquidation.
• The delisting from Nasdaq could materially adversely impact the ability to locate another target for an initial business combination.
• Warrants may expire worthless if a Business Combination is not consummated.
• Ongoing material weakness in internal control over financial reporting related to the review and reconciliation of liabilities and prepaid expenses.
• Adverse developments in the economy and capital markets, including geopolitical conflicts, inflation, and interest rates, could negatively affect the company's financial position and search for a target.

Future Outlook

The company's primary future outlook is to consummate an initial Business Combination by November 15, 2025. If successful, the surviving company (expected to be renamed Phytanix, Inc.) intends to apply for listing on the Nasdaq Capital Market. Failure to complete a Business Combination by the deadline will result in liquidation, with shareholders losing the opportunity for appreciation and warrants expiring worthless. The company is also committed to addressing its internal control material weakness.

Management Comments

• Management has determined that the liquidity condition and the date for mandatory liquidation and subsequent dissolution raises substantial doubt about the company's ability to continue as a going concern.
• Management believes that the financial statements included in this Quarterly Report present fairly in all material respects the financial position, results of operations and cash flows for the period presented, despite the identified material weakness in internal control over financial reporting.
• Management has undertaken remediation steps to address the material weakness, including increasing management review processes over liabilities, but there is no assurance it will effectively address the material weaknesses.

Industry Context

The termination of the business combination with Phytanix Bio and the delisting from Nasdaq highlight the significant challenges faced by SPACs in the current regulatory and market environment. The SEC's increased scrutiny, particularly regarding the Investment Company Act, has led SPACs like Chain Bridge I to adjust their investment strategies (e.g., holding funds in U.S. treasury securities) which can impact potential returns. The ongoing struggle to find and complete a suitable business combination within mandated timelines is a common theme in the SPAC industry, leading to liquidations or transitions to OTC markets for many. The company's situation reflects the broader trend of increased investor redemptions and a more difficult fundraising landscape for SPACs.

Comparison to Industry Standards

• The termination of the business combination with Phytanix Bio is a significant setback, contrasting with successful de-SPAC transactions seen in the industry, such as those completed by other SPACs that have merged with operating companies and maintained their exchange listings.
• The delisting from Nasdaq and subsequent trading on OTC markets places Chain Bridge I in a less favorable position compared to SPACs that successfully maintain their listing on major exchanges post-IPO or de-SPAC, which typically offer greater liquidity and investor visibility.
• The company's repeated extensions of its business combination deadline and reliance on sponsor contributions for survival are indicative of the difficulties many SPACs face in identifying and closing suitable targets, a challenge that has become more pronounced across the SPAC market compared to the peak activity years.

Management Changes

Corporate Governance

Related Party Transactions

• Fulton AC agreed to loan the Company up to $1.5 million via the Fulton AC Note (later exchanged for the Exchange Note) at no interest, convertible into warrants.
• The Company pays Fulton AC up to $30,000 per month for office space, administrative, and support services under the Fulton Services Agreement.
• Fulton AC contributed funds to the Trust Account to extend the company's life and will continue monthly contributions.
• CB Co-Investment's $1.15 million loan was converted into contingently issuable Private Placement Warrants upon consummation of a Business Combination, with specific allocations to Fulton AC, CBG, and CB Co-Investment.
• CBG and CB Co-Investment initially paid $25,000 for Class B ordinary shares and later transferred/forfeited shares.
• RSU grants to directors and officers (e.g., Mr. Silberman, Mr. Baron, Mr. Wiener, Mr. Lazarus) are contingent on a Business Combination and shareholder approval of an incentive plan.
• The Bridge Financing Note of $1,590,995.12 from Phytanix Bio (the former business combination target) is an unsecured, non-interest bearing promissory note.

Stakeholder Impact

• Shareholders: Face significant uncertainty due to the terminated merger, delisting, and going concern warning. Those holding Class A ordinary shares are subject to possible redemption if a business combination is not completed by November 15, 2025. Warrants may expire worthless. The delisting reduces liquidity and market visibility.
• Employees/Management: Management changes have occurred, and RSU grants are contingent on a successful business combination, impacting their potential compensation.
• Creditors: The going concern warning and liquidity deficit indicate increased risk for creditors, although the Trust Account funds are protected for public shareholders' redemptions.
• Sponsor (Fulton AC): Continues to provide financial support and has significant influence through voting agreements and related party loans, bearing much of the financial burden for extensions.

Next Steps

• Identify and consummate a new initial Business Combination by November 15, 2025.
• Address and remediate the material weakness in internal control over financial reporting.
• If a Business Combination is consummated, apply to list the surviving company's securities on the Nasdaq Capital Market.
• Continue to receive monthly contributions from Fulton AC to extend the company's operational period.

Key Dates

Recommendation

Keywords

SPAC, 10-Q, Quarterly Report, Chain Bridge I, Phytanix Bio, Business Combination, Delisting, Going Concern, Financial Results, SEC Filing, Corporate Governance, Risk Factors, Warrants, Trust Account, Liquidity, Internal Controls